| abstract |
The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising 4'-cyano-α',α',α'-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropriono-m-toluidide (compound I) and tamoxifen. The product comprises compound I and tamoxifen in a ratio of 25 to 350:0.5 to 100 respectively. The invention also relates to a method of providing an anti-antrogenic effect and an anti-oestrogenic effect in a patient, wherein the anti-oestrogenic effects is provided substantially without causing an additional increase in the levels of circulating androgens. |